Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)

This was a non-interventional, observational program in which Lucrin Depot (leuprorelin acetate) and add-back therapy (hormone and non-hormone) were prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication (for leuprorelin acetate) and with regards to the local guidelines or therapeutic recommendation (for add-back therapy).

The rationale for the study was the necessity to characterize the patient population and long-term leuprorelin acetate administration in the Russian Federation. Further, it was important to characterize the compliance, tolerability, and safety profile of this therapy in the routine clinical care setting in the Russian Federation.

Inclusion criteria

• Age from 18 to 50 years
• Written Patient Consent for Use/Disclosure of Data
• Diagnosis of genital endometriosis confirmed by laparoscopy (external genital endometriosis) or ultrasound (internal genital endometriosis)
• Candidate for treatment with Lucrin Depot for 6-month course
• Patients with suspected endometriosis suffering from chronic pelvic pain if other reasons for pain are excluded

Exclusion criteria

• Contraindications to administration of Lucrin Depot (leuprorelin):

• Hypersensitivity to leuprorelin similar products of protein origin or any of the excipients in drug product composition
• Vaginal bleedings of unknown etiology
• Hysterectomy
• Pregnancy and lactation
• Menopause (absence of cyclic menstrual hemorrhages for 1 year before the start of this program)
• Acute infectious period, inclusive of acute inflammatory diseases of small pelvic organs
• Other contraindications that make the patients participation impossible (by investigator judgment)
• Previous enrollment in the present program
• Extra-genital endometriosis